Bank of New York Mellon Corp Sells 35,918 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Bank of New York Mellon Corp trimmed its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 34.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,247 shares of the company’s stock after selling 35,918 shares during the quarter. Bank of New York Mellon Corp owned 0.18% of iTeos Therapeutics worth $516,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Point72 DIFC Ltd acquired a new position in shares of iTeos Therapeutics in the third quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in iTeos Therapeutics in the 3rd quarter valued at $102,000. Quest Partners LLC boosted its stake in iTeos Therapeutics by 914.7% in the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after purchasing an additional 9,934 shares during the period. Clear Harbor Asset Management LLC bought a new position in iTeos Therapeutics during the 4th quarter worth about $96,000. Finally, SG Americas Securities LLC raised its stake in shares of iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after purchasing an additional 1,508 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ITOS. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $6.70 on Friday. The stock has a 50 day moving average price of $7.30 and a 200 day moving average price of $8.51. The stock has a market capitalization of $255.90 million, a PE ratio of -2.13 and a beta of 1.38. iTeos Therapeutics, Inc. has a 52 week low of $6.32 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.13. As a group, research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.